Isha Mol

Triple-class exposed/refractory multiple myeloma (TCE/R MM; ie, patients who have been exposed to/become refractory to a proteasome inhibitor, an immunomodulatory drug, and a monoclonal antibody) remains an incurable disease with a poor prognosis and an estimated median survival of up to 12 months based on real-world United States (US) and European data.1–3 In recent years, novel therapy options have been developed for TCE/R MM, such as chimeric antigen receptor-T cell therapies, nuclear...